Global Antimalarial Drugs Market Size, Share, Trends & Forecast 2019-2025

Global Antimalarial Drugs Market Size, Share and Forecast 2019-2025

Global Antimalarial Drugs Market Size, Share, Analysis, Industry Report and Forecast to 2025

Global Antimalarial Drugs Market Trends, Size, Competitive Analysis and Forecast - 2019-2025

Global Antimalarial Drugs Market Growth, Size, Share, Industry Report and Forecast to 2019-2025

Global Antimalarial Drugs Market Size, Industry Trends, Share and Forecast 2019-2025

Global Antimalarial Drugs Market Share, Trends and Forecast to 2025

Global Antimalarial Drugs Market, Pharmaceuticals Industry, Healthcare Market, Impact of COVID-19 on Global Antimalarial Drugs Industry
Global Antimalarial Drugs Market Size, Share & Trends Analysis Report by Drug Class, By Distribution Channel, Impact of COVID-19 on Global Antimalarial Drugs Industry, and Forecast 2019-2025


The global antimalarial drugs market is expected to register lucrative growth over the forecast period 2019-2025. The growth of the market is primarily driven by a substantial increase in malaria-infected persons across the globe. According to the World Health Organization (WHO), an estimated 3.4 billion people in 92 countries are at risk of being infected with malaria and developing a disease, and 1.1 billion are at high risk in 2018. According to the World Malaria Report 2018, there were 219 million cases of malaria globally in 2017 (uncertainty range 203–262 million) and 435,000 mortalities from malaria, representing a decrease in malaria cases and deaths rates of 18% and 28% since 2010, respectively. The burden was heaviest in Africa, where an estimated 93% of all malaria fatalities occurred, and in children aged under 5 years, who accounted for 61% of all mortalities.

A full report description of Global Antimalarial Drugs Market at https://www.omrglobal.com/industry-reports/antimalarial-drugs-market

Moreover, amidst the recent outbreak of COVID-19, the demand for antimalarial drugs such as hydroxychloroquine is increasing at a rapid pace. The drug shows antiviral activity in vitro against coronaviruses, and specifically, SARS-CoV-2. Owing to the drug effectiveness, various virus affected nations have begun using hydroxychloroquine drug on the affected patients. According to the Worldometers, global coronavirus cases reached over 1.4 million with death toll around 83,000 as of 8th April 2020. With nearly 400,500 infected persons, the US is majorly affected due to the virus spread. The US is followed by Spain and Italy with cases around 146,690 and 135,586 respectively as of 8th April 2020.

Request a Free Report on Sample of Global Antimalarial Drugs Market at @ https://www.omrglobal.com/request-sample/antimalarial-drugs-market
Global Antimalarial Drugs Market Segmentation

By Drug Class

• Quinine
• Chloroquine
• Proguanil
• Mefloquine
• Others (Pyrimethamine)
• By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• E-Commerce

Regional Analysis

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

Companies Studied

• Alvizia Healthcare Pvt. Ltd.
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• IPCA Laboratories Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Cadila Healthcare Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/antimalarial-drugs-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404